- AstraZeneca and Care Access Research have forged a partnership to support the Phase III clinical trial for AZD7442.
- AZD7442 has been developed by AstraZeneca as an attempt to prevent COVID-19.
- AZD7442 is a monoclonal antibody combination.
- Participants for this trial are going to be from a wider range of professions.
- The initial trials are going to be carried out in USA and UK.
AstraZeneca and Care Access Research have teamed up to support the Phase III clinical trial for AZD7442 which is a long-acting monoclonal antibody combination which AstraZeneca has developed with the hope of preventing COVID-19.
Using Care Access’s Mobile Sites On Demand, the two partners are working to develop, deploy and manage clinical research sites across the United Kingdom (UK) to assess the safety and efficacy of AZD7442 for post-exposure prophylaxis as well as preemptive treatment. Ahmad Namvargolian, the CEO of Care Access, said in a statement that traditional methods limited who could participate in a clinical trial and how quickly the clinical trial could be completed. Mr. Namvargolian expressed happiness about providing the innovative capabilities to AstraZeneca which the latter needed to expedite clinical research operations for the important COVID-19 treatment antibody combination.
According to the current plans of two partners, the trial is going to include approximately 1,125 participants over the age of 18 in the United States of America (USA) and UK who have been exposed to COVID-19. The trial will not only include people living or working at long-term care facilities, it will also include those people who are in industrial and military settings.